1.Survivin may be a Key Target for Oxaliplatin.
Journal of the Korean Society of Coloproctology 2010;26(4):239-239
No abstract available.
Organoplatinum Compounds
2.Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
Hannah WOOPEN ; Klaus PIETZNER ; Rolf RICHTER ; Christina FOTOPOULOU ; Thomas JOENS ; Elena Ioana BRAICU ; Hakan MELLSTEDT ; Sven MAHNER ; Horst LINDHOFER ; Silvia DARB-ESFAHANI ; Carsten DENKERT ; Jalid SEHOULI
Journal of Gynecologic Oncology 2014;25(3):221-228
OBJECTIVE: Epithelial cell adhesion molecule (EpCAM) has experienced a renaissance lately as a binding site for targeted therapy as well as a prognostic marker in epithelial malignancies. Aim of this study was to study EpCAM as a potential prognostic marker in epithelial ovarian cancer (EOC). METHODS: EpCAM expression was assessed by immunohistochemistry on paraffin-embedded primary EOC-tissue samples. EpCAM overexpression was defined as an expression of EpCAM of 76% to 100%. Tissue samples and clinical data were systematically collected within the international and multicenter "Tumorbank Ovarian Cancer" network. RESULTS: Seventy-four patients, diagnosed with EOC between 1994 and 2009, were included in the study (median age, 56 years; range, 31 to 86 years). The majority of the patients (81.1%) presented with an advanced stage International Federation of Gynecology and Obstetrics (FIGO) III/IV disease. Histology was of the serous type in 41 patients (55.4%), endometrioid in 19 (25.6%), and mucinous in 14 (19%). EpCAM was overexpressed in 87.7%. Serous tumors overexpressed EpCAM significantly more often than mucinous tumors (87.8% vs. 78.6%, p=0.045); while no significant difference was noted between the other histological subgroups. EpCAM overexpression was significantly associated with a better progression free survival and higher response rates to platinum based chemotherapy (p=0.040 and p=0.048, respectively). EpCAM was identified as an independent prognostic marker for overall survival (p=0.022). CONCLUSION: Our data indicate a significant association of EpCAM overexpression with a more favorable survival in EOC-patients. Serous cancers showed a significant EpCAM overexpression compared to mucinous types. Larger multicenter analyses are warranted to confirm these findings.
Adult
;
Aged
;
Aged, 80 and over
;
Antigens, Neoplasm/*metabolism
;
Antineoplastic Agents/*therapeutic use
;
Carboplatin/therapeutic use
;
Cell Adhesion Molecules/*metabolism
;
Female
;
Humans
;
Kaplan-Meier Estimate
;
Middle Aged
;
Neoplasm Proteins/metabolism
;
Neoplasm Staging
;
Neoplasms, Glandular and Epithelial/*diagnosis/drug therapy/pathology
;
Organoplatinum Compounds/*therapeutic use
;
Ovarian Neoplasms/*diagnosis/drug therapy/pathology
;
Paclitaxel/therapeutic use
;
Prognosis
;
Tissue Banks
;
Treatment Outcome
;
Tumor Markers, Biological/*metabolism
3.Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.
Munetaka TAKEKUMA ; Shiho KUJI ; Aki TANAKA ; Nobutaka TAKAHASHI ; Masakazu ABE ; Yasuyuki HIRASHIMA
Journal of Gynecologic Oncology 2015;26(3):185-192
OBJECTIVE: The concept of platinum sensitivity and cross-resistance among platinum agents are widely known in the management of recurrent ovarian cancer. The aim of this study was to evaluate two hypotheses regarding the validity of the concept of platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer. METHODS: In this retrospective study, the clinical data of patients with recurrent cervical cancer, who had a history of receiving cisplatin based chemotherapy (including concurrent chemoradiotherapy [CCRT] with cisplatin) and who received second-line chemotherapy at the time of recurrence between April 2004 and July 2012 were reviewed. RESULTS: In total, 49 patients-34 squamous cell carcinomas (69.4%) and 15 non-squamous cell carcinomas (30.6%)-were enrolled. The median age was 53 years (range, 26 to 79 years). Univariate and multivariate analysis showed that a platinum free interval (PFI) of 12 months has a strong relationship with the response rate to second-line chemotherapy. Upon multivariate analysis of survival after second-line platinum-based chemotherapy, a PFI of 12 months significantly influenced both progression-free survival (hazard ratio [HR], 0.349; 95% confidence interval [CI], 0.140 to 0.871; p=0.024) and overall survival (HR, 0.322; 95% CI, 0.123 to 0.842; p=0.021). In patients with a PFI of less than 6 months, the difference of progression-free survival between patients with re-administration of cisplatin (3.0 months) and administration of cisplatin analogue (7.2 months) as second-line chemotherapy was statistically significant (p=0.049, log-rank test). CONCLUSION: The concept of platinum sensitivity could be applied to recurrent cervical cancer and there is a possibility of noncross-resistance of cisplatin analogue with cisplatin.
Adult
;
Aged
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Carboplatin/administration & dosage
;
Carcinoma, Squamous Cell/*drug therapy/mortality
;
Cisplatin/administration & dosage/*analogs & derivatives
;
Drug Resistance, Neoplasm
;
Female
;
Humans
;
Kaplan-Meier Estimate
;
Middle Aged
;
Neoplasm Recurrence, Local/*drug therapy
;
Organoplatinum Compounds/administration & dosage
;
Retreatment
;
Retrospective Studies
;
Treatment Outcome
;
Uterine Cervical Neoplasms/*drug therapy/mortality
4.Experimental study of sensitivity to chemotherapeutic agents for human endometrial carcinoma cell line.
Xiu-gui SHENG ; Ling TANG ; Da-peng LI ; Hui-qin LI ; Xian-rang SONG ; Chun-hua LU ; Xing-wu WANG ; Qing-shui LI
Chinese Journal of Oncology 2004;26(7):409-412
OBJECTIVETo screen the sensitive chemotherapeutic agents to human endometrial carcinoma cell line-1 (HECCL-1) and study its mechanism.
METHODSMTT method was used to examine the relative inhibition ratios (RIRs) of various concentrations of 18 chemotherapeutic agents to HECCL-1. Cell cycle, apoptosis and expression of MDR1 protein were detected by FCM.
RESULTSNine of the chemotherapeutic agents studied obviously inhibited the proliferative activity of HECCL-1 in a dose-dependent manner. The order of sensitivity was as follows: adriamycin (ADM), oxaliplatin (L-OHP), carboplatin (CBP), cisplatin (DDP), taxol (TAL), epirubicin (EPI), mitoxantrone (MIT), dactomycin (ACTD) and 5-fluorouracil (5-Fu). FCM showed these agents could significantly reduce the proportion of cells in G0-G1 phase, and increase the proportion of cells in S and G2-M phase (P < 0.05). Cell apoptosis was observed in 11 chemotherapeutic agents at their peak concentration. MDR expression was induced after using EPI, 5-Fu, hydroxycamptothecin (HCPT) and MIT.
CONCLUSIONHECCL-1 is sensitive to a number of the chemotherapeutic agents studied. Induced apoptosis may be the major mechanism of drug sensitivity, and acquired drug-resistance may be the critical reason against continued administration.
ATP-Binding Cassette, Sub-Family B, Member 1 ; metabolism ; Antineoplastic Agents ; administration & dosage ; pharmacology ; Apoptosis ; drug effects ; Carboplatin ; administration & dosage ; pharmacology ; Cell Cycle ; drug effects ; Cell Line, Tumor ; Dose-Response Relationship, Drug ; Doxorubicin ; administration & dosage ; pharmacology ; Drug Resistance, Multiple ; Drug Resistance, Neoplasm ; Endometrial Neoplasms ; metabolism ; pathology ; Epirubicin ; administration & dosage ; pharmacology ; Female ; Fluorouracil ; administration & dosage ; pharmacology ; Humans ; Organoplatinum Compounds ; administration & dosage ; pharmacology
5.Adjuvant Chemotherapy in Colon Cancer.
Korean Journal of Medicine 2012;83(3):297-304
Colorectal cancer represents a major public health problem in worldwide including Korea. According to the National Cancer Registry, colon cancer is the third most common cancer and the forth leading cause of cancer death. The surgery is a main treatment option for cure. Despite curative surgery in those presenting early, the risk of relapse is significantly high. To improve the survival, huge advances have been made in the treatment of colon cancer over the last decade. Especially, the median overall survival time for stage IV colon cancer has been reached from 6-9 months to over 20 months. Based on these results, drugs such as irinotecan, oxaliplatin and oral fluoropyrimidine have been used to evaluate the efficacy in adjuvant setting. Oxaliplatin based chemotherapy is now emerging as the standard of care in adjuvant treatment of stage III colon cancer. Targeted agents, which have shown promise in the metastatic setting, are currently being examined in the adjuvant setting, although results have been disappointing until now. Even though adjuvant treatment is recommended for 'high risk' stage II, the endeavor to answer for question-who should be treated by what-is needed.
Camptothecin
;
Chemotherapy, Adjuvant
;
Colon
;
Colonic Neoplasms
;
Colorectal Neoplasms
;
Korea
;
Organoplatinum Compounds
;
Public Health
;
Recurrence
;
Standard of Care
6.Chemotherapeutic Responsibility according to Polymorphism of ERCC1, XRCC1 and GSTP1 in Gastric Cancer Patients Receiving Oxaliplatin Based Chemotherapy.
Dae Youn WON ; Soo Hong KIM ; Hoon HUR ; Hun JUNG ; Hae Myung JEON
Journal of the Korean Surgical Society 2010;78(6):350-356
PURPOSE: The platinum-based modified FOLFOX-6 has been reported as an acceptable chemotherapeutic regimen in treatment of advanced gastric cancer patients. The response rate and drug-induced toxicity of platinum-based chemoagents is different according to several gene polymorphism such as ERCC1, XRCC1 and GSTP1 genes, which were related with therapeutic mechanisms. We aimed to evaluate the effect of gene polymorphism and determine the possibility as prediction factor for responsibility in advanced and recurrent gastric cancer patients treated with modified FOLFOX-6 regimen. METHODS: This study was conducted with 55 patients. We sampled 20 ml of peripheral blood to isolate DNA from lymphocytes, and identified genotypes of 3 genes (ERCC1, XRCC1, GSTP1) by PCR-RFL of extracted DNA. Based on medical records, retrospective analysis was made on the patients' clinical characteristics. RESULTS: The overall response rate to modified FOLFOX-6 was 40.0% (22/55). In polymorphism of ERCC1 C8092A, the wild type (CC) showed a statistically significantly lower response rates to chemoagents than the mutant type (CA/AA). In the subtypes of ERCC1 C118T, however, the wild type (CC) showed statistically significantly lower hematological toxicity than the mutant type (CA/AA). But, there was no statistically significance in survival analysis. CONCLUSION: We suggest that ERCC1 gene polymorphism is clinically more adequate as a feasible factor for predicting the response rate and toxicity of modified FOLFOX-6 regimen in gastric cancer patients.
DNA
;
Genotype
;
Humans
;
Lymphocytes
;
Medical Records
;
Organoplatinum Compounds
;
Retrospective Studies
;
Stomach Neoplasms
7.Multiple Cancers in a Patient with Systemic Sclerosis and Aggravated Interstitial Lung Disease by Chemotherapy.
Chan Kwon PARK ; Seok Jong LEE ; Hyung Jun CHO ; Kyeong Soo LEE ; Sung Jun KIM ; Gu Min CHO ; Ha Ni LEE
Tuberculosis and Respiratory Diseases 2013;75(3):111-115
Although the relationship between malignancy risk with systemic sclerosis (SSc) has been inconclusive, there are some previous studies for a positive correlation. Most patients with SSc have some degree of lung parenchymal involvement in the form of interstitial thickening and fibrosis. Interstitial lung disease is the most common pulmonary manifestation of SSc. Interstitial lung disease following chemotherapy (5-fluorouracil, leucovorin, and oxaliplatin [FOLFOX]) is an uncommon life-threatening complication and it is induced by oxaliplatin. We report a case of multiple cancers in a patient with SSc and aggravated interstitial lung disease by chemotherapy.
Fibrosis
;
Humans
;
Leucovorin
;
Lung
;
Lung Diseases, Interstitial
;
Lung Neoplasms
;
Organoplatinum Compounds
;
Scleroderma, Systemic
8.A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis.
Dong Hyun LEE ; Sung Yong OH ; Yu Rim LEE ; Seok Jae HUH ; Hyun Hwa YOON ; Sung Hyun KIM ; Suee LEE ; Ji Hyun LEE ; Young KIM ; Hyo Jin KIM ; Hyuk Chan KWON
Cancer Research and Treatment 2011;43(4):225-230
PURPOSE: Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) is common and is the second most common cause of death. Clinical studies regarding chemotherapy for CRC with PC have been classically rather limited in scope. We evaluated the efficacy of modified oxaliplatin, leucovorin, and fluorouracil (m-FOLFOX4) regimen for PC of CRC origin. MATERIALS AND METHODS: CRC patients with PC were treated with cycles of oxaliplatin at 85 mg/m2 on day 1, leucovorin 20 mg/m2 followed by 5-fluorouracil (5-FU) via a 400 mg/m2 bolus and a 22 hours continuous infusion of 600 mg/m2 5-FU on days 1-2 at 2-week intervals. RESULTS: Forty patients participated in this study. Median age was 55 years. Thirty-two patients (80.0%) received previous operation, and 60.0% of PC occurred synchronously. Thirty-five patients (87.5%) were assessable and exhibited measurable lesions. Two patients (5.7%) demonstrated complete response and five patients (14.3%) showed partial response. The median time to progression was 4.4 months (95% confidence interval, 2.5 to 6.3 months), the median overall survival time was 21.5 months (95% confidence interval, 17.2 to 25.7 months). There was no treatment related death. Presence of liver metastasis (p=0.022), performance status (p=0.039), and carcinoembryonic antigen level (p=0.016) were related to the time to progression. Patients with low carcinoembryonic antigen level (37.2 months vs. 15.6 months, p=0.001) or good performance status (22.5 months vs. 6.8 months, p=0.040) showed better overall survival. CONCLUSION: The m-FOLFOX4 regimen was determined to be effective for CRC patients with PC.
Carcinoembryonic Antigen
;
Carcinoma
;
Cause of Death
;
Colorectal Neoplasms
;
Fluorouracil
;
Humans
;
Leucovorin
;
Liver
;
Neoplasm Metastasis
;
Organoplatinum Compounds
;
Peritoneum
9.Oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX-4) Combination Chemotherapy as a Salvage Treatment in Advanced Gastric Cancer.
Young Saing KIM ; Junshik HONG ; Sun Jin SYM ; Se Hoon PARK ; Jinny PARK ; Eun Kyung CHO ; Jae Hoon LEE ; Dong Bok SHIN
Cancer Research and Treatment 2010;42(1):24-29
PURPOSE: This study was designed to determine the efficacy and safety of FOLFOX-4 chemotherapy as a salvage treatment for patients with advanced gastric cancer (AGC). MATERIALS AND METHODS: The AGC patients with an ECOG performance status of 0~1 and progressive disease after prior treatments were registered onto this phase II trial. The patients received oxaliplatin (85 mg/m2 on day 1), leucovorin (200 mg/m2 on days 1 and 2) and 5-fluorouracil (400 mg/m2 as a bolus and 600 mg/m2 as a 22-hour infusion on days 1 and 2) every 2 weeks. RESULTS: For the 42 treated patients, a total of 228 chemotherapy cycles (median: 5, range: 1~12) were administered. Twenty-nine patients (69%) received FOLFOX-4 chemotherapy as a third-(50%) or fourth-line (19%) treatment. On the intent-to-treat analysis, 9 patients (21%) achieved a partial response, which was maintained for 4.6 months. The median progression-free survival and overall survival were 3.0 months and 6.2 months, respectively. The frequently encountered toxicities were neutropenia and gastrointestinal side effects, including anorexia. Although there was one possible treatment-related death, the toxicity profiles were generally predictable and manageable. CONCLUSION: Salvage chemotherapy with FOLFOX-4 is an effective and tolerable regimen for those heavily pretreated AGC patients who have a good performance status.
Anorexia
;
Disease-Free Survival
;
Drug Therapy, Combination
;
Fluorouracil
;
Humans
;
Leucovorin
;
Neutropenia
;
Organoplatinum Compounds
;
Stomach Neoplasms
10.FOLFOX-4 Combination Chemotherapy as a First-line Treatment in Patients with Advanced Gastric Cancer.
Korean Journal of Medicine 2012;82(1):35-36
The FOLFOX-4 regimen as first-line treatment in patients with advanced gastric cancer has not evidence of category 1 for prolongation of survival in patients with advanced gastric cancer. Therefore, the use is preferred in the second line. But, especially in elderly patients, FOLFOX regimen was active and well tolerated with lower toxicities. Further phase III study is warranted to evaluate the evidence for prolongation of survival in elderly patients or combination therapy with target agents in advanced gastric cancer.
Aged
;
Antineoplastic Combined Chemotherapy Protocols
;
Drug Therapy, Combination
;
Fluorouracil
;
Humans
;
Leucovorin
;
Organoplatinum Compounds
;
Stomach Neoplasms